Background: The concept of passive and active targeting of solid tumours with intravenously administered particulate and macromolecular carriers is an attractive one that has received considerable attention and promising results have emerged from such attempts at the clinical level. Particulate and polymeric drug carriers have the capability to deliver from 2- to 10-times more drug to solid tumours compared with the administered drug in its free form, and it is through the altered pharmacokinetics and pharmacodynamics of the encapsulated/conjugated drugs relative to free drugs that anticancer drug-induced toxicity is dramatically reduced.
Objectives: It is the intention of this article to examine the role of selected particulate and macromolecular entities as carriers of anticancer drugs and their ability to target different components of solid tumours following the intravenous route of injection, and release their cargo in a bioavailable form at levels that exceed the minimum cytotoxic concentration.
Methods: The authors of this paper have focused on carrier behaviour (pharmacokinetics of single and multiple injections, and new toxicity issues that may arise from different dosing schedules and dose intensities, as well as from the carrier itself), pathophysiological factors regulating particulate and macromolecular transport into tumours (structural arrangements of tumour vasculature, tumour vascular permeability, interstitial hypertension and interstitial transport), and biochemical and physicochemical factors controlling drug release from extravasated carriers (the bioavailable drug).
Conclusion: Nanoscale drug carriers can passively target solid tumours, but achieving therapeutic responses involves pathophysiological processes that control carrier transport into tumours and biochemical factors regulating drug release from extravasated carriers and maintaining free drug levels above the minimum cytotoxic concentration. It is conceivable that future sophistication in tumour targeting and the outcome of end results will depend on an improved understanding of tumour biology and biological barriers, as well as advances in carrier design and nanoengineering.